Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Outlook Therapeutics, Inc. (ONS)
|
Add to portfolio |
|
|
|
| Price: |
$1.39
| | Metrics |
| OS: |
260.2
|
M
| |
|
|
| Market cap: |
$362
|
M
| |
|
|
|
Net debt:
|
$35.8
|
M
| |
|
|
|
EV:
|
$397
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 8.1 | 3.1 | 3.8 | 3.0 | 5.2 |
| Revenue growth | | | -100.0% | 163.8% | -19.0% | 27.9% | -42.9% | -42.3% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 8.1 | 3.1 | 3.8 | 3.0 | 5.2 |
| Gross margin | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 42.3 | 39.0 | 26.3 | 23.8 | 18.5 | 23.8 | 32.8 | 38.9 |
| General and administrative | 20.7 | 12.8 | 10.0 | 9.4 | 14.2 | 15.9 | 21.6 | 12.9 |
| EBIT | -63.0 | -51.7 | -36.3 | -25.0 | -29.6 | -35.9 | -51.3 | -46.6 |
| EBIT margin | | | | -307.2% | -960.1% | -941.4% | -1723.3% | -892.1% |
| Pre-tax income | -66.0 | -53.2 | -38.5 | -37.9 | -33.7 | -38.3 | -53.2 | -48.9 |
| Income taxes | 0.0 | 0.0 | -3.3 | -3.4 | -3.6 | 0.5 | 0.1 | -0.2 |
| Tax rate | | | 8.5% | 9.0% | 10.8% | | | 0.4% |
| Net income | -66.1 | -53.2 | -48.9 | -36.0 | -48.0 | -40.0 | -63.1 | -53.0 |
| Net margin | | | | -442.4% | -1555.2% | -1050.1% | -2119.1% | -1015.4% |
| |
| Diluted EPS | ($0.31) | ($0.35) | ($0.67) | ($1.98) | ($9.74) | ($1.66) | ($3.67) | ($5.43) |
| Shares outstanding (diluted) | 212.1 | 152.7 | 72.6 | 18.2 | 4.9 | 24.0 | 17.2 | 9.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|